Johnson & Johnson’s Oncology Care Index reveals 73% of oncologists see a gap between new cancer treatments and clinical ...

Phase III POTOMAC trial showed that adding Durvalumab (Imfinzi) to BCG induction and maintenance therapy significantly ...

For the first time, the FDA completed a generative AI-assisted scientific review pilot, cutting review tasks from days to ...

The Phase III DESTINY-Breast11 trial showed Enhertu followed by THP significantly improved pathologic complete response (pCR) ...

The phase II ROME trial demonstrated that personalized therapy guided by combined tissue and liquid biopsies significantly ...

Bayer has launched a first-in-human clinical trial for 225Ac-GPC3 (BAY 3547926), a novel targeted alpha radiopharmaceutical ...

The first AI-powered companion diagnostic for non-small cell lung cancer has received FDA Breakthrough Device Designation.

Researchers from Karolinska Institutet developed a non-invasive urine test for early prostate cancer detection, utilizing AI, ...

Zoldonrasib, an oral KRAS G12D-selective inhibitor, showed a 61% response rate and 89% disease control in previously treated ...